首页> 外国专利> CLINICAL DIAGNOSIS OF HEPATIC FIBROSIS USING A NOVEL PANEL OF HUMAN SERUM PROTEIN BIOMARKERS

CLINICAL DIAGNOSIS OF HEPATIC FIBROSIS USING A NOVEL PANEL OF HUMAN SERUM PROTEIN BIOMARKERS

机译:新型人血清蛋白生物标志物诊断肝纤维化的临床研究

摘要

The inventors have proposed a novel panel of human serum protein biomarkers for diagnosing hepatic fibrosis and cirrhosis. Presently there is no reliable non-invasive way of assessing liver fibrosis. A 2D-PAGE based proteomics study was used to identify potential fibrosis biomarkers. Serum from patients with varying degrees of hepatic scarring induced by infection with the hepatitis C virus (HCV) was analysed. Several proteins associated with liver scarring and/or viral infection were identified. These proteins include the inter-α-trypsin inhibitor heavy chain H4 fragments, complement factor H-related protein 1, CD5L, Apo L1, and β2GPI. Increased and decreased thiolester cleavage of a2M and Complement C3, respectively, was also detected. The concentrations of these novel biomarkers can be determined using an immunoassay where the concentrations would reflect the extent of fibrosis. A fibrosis scoring scale for each of the novel biomarkers is proposed. The additive result from the scores of all the novel biomarkers would give a more reliable indication of the degree of fibrosis rather than examining individual biomarkers.
机译:发明人提出了用于诊断肝纤维化和肝硬化的新型人血清蛋白生物标记物。目前,尚无可靠的评估肝纤维化的非侵入性方法。基于2D-PAGE的蛋白质组学研究用于鉴定潜在的纤维化生物标志物。分析了丙型肝炎病毒(HCV)感染引起的不同程度肝瘢痕形成患者的血清。鉴定了几种与肝瘢痕形成和/或病毒感染有关的蛋白质。这些蛋白包括α-胰蛋白酶抑制剂之间的重链H4片段,补体因子H相关蛋白1,CD5L,Apo L1和β2GPI。还分别检测到a2M和补体C3的巯基酯切割增加和减少。这些新的生物标志物的浓度可以使用免疫测定法确定,其中所述浓度将反映纤维化程度。提出了每种新型生物标志物的纤维化评分量表。所有新颖生物标志物得分的累加结果将提供纤维化程度的更可靠指示,而不是检查单个生物标志物。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号